why choose us

First received: February 20, 2024

Clinical Trial: A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Bronchiectasis

Study Type: INTERVENTIONAL


Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bro

Brief Summary: ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups.The purpose of this study is to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive).Study details include:The study duration (screening, 24-52-week treatment, 20-week safety follow-up) will be up to 47-77 weeks.The treatment duration…

Read more